Topic summary
Sigma-Tau
Extracted from the Wikipedia article Leadiant Biosciences.
Structure of Sigma-Tau group
Sigma-Tau in collaboration with the non-profit organization Medicines for Malaria Venture (MMV) has developed a new medicine for the treatment of malaria a fixed combination consisting of dihydroartemisinin and piperaquine, judged to be one of the most effective antimalaria medicines available and the best combination containing artemisinin. The registration dossier was presented on July 3, 2009, in Europe (EMEA)and approved in 2011. The new drug has obtained registration in Cambodia, Ghana, and Tanzania and is started in Burkina Faso, Mozambique, and other key African endemic countries.